Objective: Evaluate the correlation between dyskinesia and quality of life (QoL) at baseline and after 12 months of treatment with levodopa-carbidopa intestinal gel (LCIG) in patients with advanced Parkinson’s disease (PD).
Background: To provide optimal treatment regimens for patients in advanced stages of PD, it is important to understand how changes in dyskinesia affect patients’ QoL.
Method: DUOdopa/Duopa in Patients with Advanced Parkinson’s Disease—a GLobal OBservational Study Evaluating Long-Term Effectiveness (DUOGLOBE)—is an ongoing multi-country, single-arm, post-marketing observational study assessing the long-term effectiveness of LCIG in patients with advanced PD (NCT02611713). Assessments included the Unified Dyskinesia Rating Scale (UDysRS) and Parkinson’s Disease Questionnaire (PDQ-8) prior to and at 12 months LCIG therapy. Patients who were followed up for 12 months and completed all 4 assessments were included in this post hoc analysis of an interim dataset.
Results: For this dataset, the baseline UDysRS score was 33.7 ± 21.1 points (n = 152), and the baseline PDQ-8 score was 45.1 ± 18.1 points (n = 171) with a Pearson correlation coefficient between the 2 measures of 0.2732 (P < .001), indicating a weak, yet significant correlation [figure1]. After 12 months of receiving LCIG treatment, patients’ UDysRS scores reduced by an average of 9.6 ± 22.5 points (n = 117) and PDQ-8 scores reduced by 9.0 ± 21.6 points (n = 135) with a Pearson correlation coefficient of 0.2345, indicating a significant positive correlation between the improvements (P = .011) [figure2].
Conclusion: In this cohort of patients with advanced PD, UDysRS and PDQ-8 scores were significantly correlated at baseline, suggesting that dyskinesia negatively impacts patients’ QoL. After 12 months of LCIG treatment, improvement in QoL was positively correlated with improvement of dyskinesia.
To cite this abstract in AMA style:
J. L Aldred, F. E Pontieri, L. Bergmann, T. Gao, P. Kukreja, P. Bourgeois, N. Kovács. Correlation Between Dyskinesia and Quality of Life at Baseline and After 12 months of Treatment with LCIG in Patients with Advanced Parkinson’s Disease [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/correlation-between-dyskinesia-and-quality-of-life-at-baseline-and-after-12-months-of-treatment-with-lcig-in-patients-with-advanced-parkinsons-disease/. Accessed June 15, 2025.« Back to MDS Virtual Congress 2020
MDS Abstracts - https://www.mdsabstracts.org/abstract/correlation-between-dyskinesia-and-quality-of-life-at-baseline-and-after-12-months-of-treatment-with-lcig-in-patients-with-advanced-parkinsons-disease/